Table 1.
Clinical features of our Alzheimer’s Disease Italian cohort, stratified according to gender.
| Gender (F/M) | 241/121 | Female | Male |
|---|---|---|---|
| Age (years) | 80.5 ± 7.0 | 80.9 ± 7.1 | 79.7 ± 6.7 |
| Schooling (years) | 6.0 ± 3.6 | 5.4 ± 2.9 | 7.4 ± 4.4 |
| MMSE, total score | 11.7 ± 7.3 | 12.0 ± 6.9 | 10.9 ± 8.1 |
| Onset (years) | 76.1 ± 7.9 | 76.5 ± 8.1 | 75.4 ± 7.6 |
| Illness Duration (years) | 4.5 ± 2.9 | 4.4 ± 2.6 | 4.5 ± 3.5 |
| BMI | 22.3 ± 4.1 | 22.2 ± 4.2 | 22.5 ± 3.8 |
| IADL | 7.2 ± 1.5 | 7.4 ± 1.2 | 6.8 ± 1.9 |
| BADL | 3.7 ± 1.9 | 3.6 ± 1.9 | 3.8 ± 1.8 |
| Tinetti | 19.8 ± 5.4 | 19.8 ± 5.2 | 19.6 ± 5.9 |
| CIRS | 12.7 ± 9.7 | 12.2 ± 9.5 | 13.8 ± 10.0 |
| Hypertension | 27.9% | 29.5% | 24.8% |
| Cardiopathy | 28.7% | 26.1% | 33.9% |
| Hypercholesterolemia | 4.7% | 5.8% | 2.5% |
| Diabetes | 6.6% | 5.4% | 9.1% |
| Psychiatric diseases | 26.0% | 27.4% | 23.1% |
| AChEIs | 20.2% | 21.6% | 17.4% |
| Neuroleptics | 45.5% | 41.1% | 51.2% |
| Antidepressants | 45.6% | 46.9% | 43.0% |
| Benzodiazepines/hypnotics | 41.4% | 46.1% | 32.2% |
Note: The measurement data are expressed as mean ± standard deviation (mean ± SD) or in percentual (%). MMSE: Mini-Mental State Examination; BMI: Body max index; IADL: Instrumental activities daily living; BADL: Basic activities of daily living; Tinetti; CIRS: Cumulative illness rating scales; AChEIs: Acetylcholinesterase inhibitors.